Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0031

Medical education · Dr. Mariana Rossi

04 May 2026 · Phone · Dr. Mariana Rossi, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0031—

Capture insight from this engagement

Location: Royal Marsden
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Sequencing after progression

Scientific content used

PD-L1 testing pathway infographic
irAE management guide

Questions raised

Is there subgroup data for patients with untreated brain metastases?
What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Medical education with pathologist at Royal Marsden. Discussed brain-metastasis subgroup data, sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 4
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0031

Audit history (0)

All create, update and approval events for this record

No audit events in sample data